"LONG-TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW-UP" by M. Montillo

Selected Works of John M. Pagel, MD, PhD

Article

LONG-TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW-UP

Hematological Oncology (2017)

M. Montillo, Catholic University of the Sacred Heart
J.C. Byrd, Ohio State University
P. Hillmen
S. O'Brien, University of California, Irvine
J.C. Barrientos, Hofstra University
N.M. Reddy, Vanderbilt University
S. Coutre, Stanford University
C.S. Tam, Peter MacCallum Cancer Centre
S.P. Mulligan, Royal North Shore Hospital
U. Jaeger, Medical University of Vienna
P.M. Barr, University of Rochester Medical Center
R.R. Furman, Cornell University
T.J. Kipps, University of California, San Diego
P. Thornton, Beaumont Hospital
C. Moreno
J.M. Pagel, Cancer Institute
J.A. Burger, University of Texas MD Anderson Cancer Center
J. Jones, Ohio State University
S. Dai
R. Vezan
D.F. James
J.R. Brown, Harvard University

Link

Disciplines

Publication Date

January 6, 2017

DOI

10.1002/hon.2438_98

Citation Information

M. Montillo, J.C. Byrd, P. Hillmen, S. O'Brien, et al.. "LONG-TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW-UP" Hematological Oncology Vol. 35 (2017) p. 235 - 236
Available at: http://works.bepress.com/john-pagel/27/